PHARMACOECONOMIC ASPECT OF OMALIZUMAB APPLICATION AMONG THE PATIENTS, SUFFERING FROM THE BRONCHIAL ASTHMA

PHARMACOECONOMIC ASPECT OF OMALIZUMAB APPLICATION AMONG THE PATIENTS, SUFFERING FROM THE BRONCHIAL ASTHMA

Show other versions (1)

In the given article, the authors discuss the most difficult issue of the pediatrics, which is the treatment of the severe bronchial asthma. Our columnist is professor A.S. Kolbin introduces omalizumab, a new medication from the monoclonal antibodies group, to our readers. It allows practitioners to...

Full description

Bibliographic Details
Main Authors: A.S. Kolbin, N.N. Klimko, B.V. Andreev
Format: Article
Language:English
Published: Paediatrician Publishers, LLC 2008-07-01
Series:Pediatričeskaâ Farmakologiâ
Online Access:https://pf.spr-journal.ru/jour/article/view/832
id doaj-39a1fc2cca3543d08ba42754fffe5824
record_format Article
spelling doaj-39a1fc2cca3543d08ba42754fffe58242020-11-25T00:47:57ZengPaediatrician Publishers, LLCPediatričeskaâ Farmakologiâ1727-57762500-30892008-07-01543844827PHARMACOECONOMIC ASPECT OF OMALIZUMAB APPLICATION AMONG THE PATIENTS, SUFFERING FROM THE BRONCHIAL ASTHMAA.S. Kolbin0N.N. Klimko1B.V. Andreev2Saint Petersburg State UniversitySaint Petersburg Medical Academy of Postgraduate StudiesSaint Petersburg State UniversityIn the given article, the authors discuss the most difficult issue of the pediatrics, which is the treatment of the severe bronchial asthma. Our columnist is professor A.S. Kolbin introduces omalizumab, a new medication from the monoclonal antibodies group, to our readers. It allows practitioners to control the severe persistent bronchial asthma. The article accentuates the clinical effectiveness and pharmacoeconomic aspects of the medication application.Key words: bronchial asthma, severe run, treatment, monoclonal antibodies, children.https://pf.spr-journal.ru/jour/article/view/832
collection DOAJ
language English
format Article
sources DOAJ
author A.S. Kolbin
N.N. Klimko
B.V. Andreev
spellingShingle A.S. Kolbin
N.N. Klimko
B.V. Andreev
PHARMACOECONOMIC ASPECT OF OMALIZUMAB APPLICATION AMONG THE PATIENTS, SUFFERING FROM THE BRONCHIAL ASTHMA
Pediatričeskaâ Farmakologiâ
author_facet A.S. Kolbin
N.N. Klimko
B.V. Andreev
author_sort A.S. Kolbin
title PHARMACOECONOMIC ASPECT OF OMALIZUMAB APPLICATION AMONG THE PATIENTS, SUFFERING FROM THE BRONCHIAL ASTHMA
title_short PHARMACOECONOMIC ASPECT OF OMALIZUMAB APPLICATION AMONG THE PATIENTS, SUFFERING FROM THE BRONCHIAL ASTHMA
title_full PHARMACOECONOMIC ASPECT OF OMALIZUMAB APPLICATION AMONG THE PATIENTS, SUFFERING FROM THE BRONCHIAL ASTHMA
title_fullStr PHARMACOECONOMIC ASPECT OF OMALIZUMAB APPLICATION AMONG THE PATIENTS, SUFFERING FROM THE BRONCHIAL ASTHMA
title_full_unstemmed PHARMACOECONOMIC ASPECT OF OMALIZUMAB APPLICATION AMONG THE PATIENTS, SUFFERING FROM THE BRONCHIAL ASTHMA
title_sort pharmacoeconomic aspect of omalizumab application among the patients, suffering from the bronchial asthma
publisher Paediatrician Publishers, LLC
series Pediatričeskaâ Farmakologiâ
issn 1727-5776
2500-3089
publishDate 2008-07-01
description In the given article, the authors discuss the most difficult issue of the pediatrics, which is the treatment of the severe bronchial asthma. Our columnist is professor A.S. Kolbin introduces omalizumab, a new medication from the monoclonal antibodies group, to our readers. It allows practitioners to control the severe persistent bronchial asthma. The article accentuates the clinical effectiveness and pharmacoeconomic aspects of the medication application.Key words: bronchial asthma, severe run, treatment, monoclonal antibodies, children.
url https://pf.spr-journal.ru/jour/article/view/832
work_keys_str_mv AT askolbin pharmacoeconomicaspectofomalizumabapplicationamongthepatientssufferingfromthebronchialasthma
AT nnklimko pharmacoeconomicaspectofomalizumabapplicationamongthepatientssufferingfromthebronchialasthma
AT bvandreev pharmacoeconomicaspectofomalizumabapplicationamongthepatientssufferingfromthebronchialasthma
_version_ 1725257722261143552

Similar Items